Skip to content

US · MGTX · BIOTECHNOLOGY

MeiraGTx Holdings plc (MGTX) intrinsic value and stock valuation

$7.98as of 2026-11-21 · Mkt cap 1.16B

Data updated · price as of 2026-11-21

Strongly undervaluedIC value is more than 50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

MeiraGTx Holdings plc DCF and intrinsic value

InvestorsCraft values MGTX with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from MGTX’s statements →

MeiraGTx Holdings plc Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York City, NY 10016 meiragtx.com

How the business is doing

Fiscal 2016–2025, USD

Revenue
$81.4M+39.2% 5y CAGRd
20162025
Net income
-$-114.2M
20162025
Free cash flow
-$-50.19M
20162025
Total equity
-$-5.79M
20162025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2016–2025, USD
20252024202320222021
Revenue$81.4M$33.3M$14M$15.9M$37.7M
Operating income-$-105.97M-$-164.21M-$-137.06M-$-116.36M-$-72.76M
Net income-$-114.2M-$-147.79M-$-84.03M-$-129.62M-$-79.56M
EPSd-$-1.42M-$-2.12M-$-1.49M-$-2.87M-$-1.8M
Operating cash flow-$-46.36M-$-104.5M-$-105.36M-$-73.1M-$-10.53M
Capital expenditure-$-3.83M-$-4.96M-$-20.17M-$-44.96M-$-55.22M
Free cash flow-$-50.19M-$-109.45M-$-125.54M-$-118.06M-$-65.75M
Total assets$244.4M$269.8M$326.7M$318.2M$320.2M
Total debt$88.7M$84.8M$89.3M$92.3M$23.7M
Net debt$22.8M-$-18.86M-$-40.3M-$-23.27M-$-113.97M
Total equity-$-5.79M$67.8M$138.2M$117.7M$185.4M
Cash and short-term investments$65.9M$103.7M$129.6M$115.5M$137.7M
Income statement
20252024202320222021
Revenue$81.4M$33.3M$14M$15.9M$37.7M
Cost of revenue$4.84M$23.8M$0.00$0.00$0.00
Gross profit$76.6M$9.49M$14M$15.9M$37.7M
Research and development expenses$129.6M$119.5M$103.8M$85.7M$66.7M
Selling, general and administrative expenses$52.9M$54.2M$47.3M$46.6M$43.8M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$182.5M$173.7M$151.1M$132.3M$110.5M
Cost and expenses$187.4M$197.5M$151.1M$132.3M$110.5M
Interest income$1.82M$4.14M$2.27M$780K$210K
Interest expense$12.2M$13.3M$13.2M$4.95M$290K
Depreciation and amortization$12.6M$12.8M$13.7M$8.6M$7.87M
Ebitda-$-89.4M-$-121.69M-$-57.05M-$-116.07M-$-71.4M
Operating income-$-105.97M-$-164.21M-$-137.06M-$-116.36M-$-72.76M
Total other income/expenses, net-$-8.23M$16.4M$53M-$-13.26M-$-6.8M
Income before tax-$-114.2M-$-147.79M-$-84.03M-$-129.62M-$-79.56M
Income tax expense$0.00$0.00$0.00$0.00$0.00
Net income-$-114.2M-$-147.79M-$-84.03M-$-129.62M-$-79.56M
Weighted average shares outstanding$80.4M$69.8M$56.5M$45.2M$44.1M
Weighted average diluted shares outstanding$80.4M$69.8M$56.5M$45.2M$44.1M
Balance sheet
20252024202320222021
Cash and short-term investments$65.9M$103.7M$129.6M$115.5M$137.7M
Net receivables$18.3M$10.6M$23.4M$29M$35M
Inventory$0.00$390K$0.00$0.00$0.00
Total current assets$91.8M$123.5M$159.6M$154.3M$183.2M
Property, plant and equipment, net$141.9M$135.7M$156.2M$154.1M$126.3M
Goodwill and intangible assets$580K$820K$1.12M$2.08M$2.57M
Long-term investments$6.75M$6.75M$6.77M$6.33M$6.66M
Total non-current assets$152.7M$146.2M$167.1M$163.9M$136.9M
Total assets$244.4M$269.8M$326.7M$318.2M$320.2M
Accounts payable$10.1M$23.6M$16M$16.6M$15.4M
Short-term debt$27.5M$4.05M$4.19M$3.88M$3.37M
Deferred revenue$1.78M$4.83M$2.93M$15.1M$21.8M
Total current liabilities$122.6M$60.8M$67.1M$82.1M$68.1M
Long-term debt$61.2M$80.7M$85.1M$88.4M$20.4M
Deferred revenue, non-current$65.1M$57.6M$34M$27.4M$43.1M
Total non-current liabilities$127.7M$141.1M$121.5M$118.4M$66.6M
Capital lease obligations$14.4M$11.6M$17.1M$21.2M$23.7M
Total liabilities$250.2M$201.9M$188.6M$200.5M$134.8M
Common stock$0.00$0.00$0.00$0.00$0.00
Retained earnings-$-816.22M-$-702.02M-$-554.23M-$-470.2M-$-340.59M
Accumulated other comprehensive income (loss)$2.41M-$-3.72M-$-1.44M$6.05M-$-2.67M
Total equity-$-5.79M$67.8M$138.2M$117.7M$185.4M
Total investments$6.75M$6.75M$6.77M$6.33M$6.66M
Total debt$88.7M$84.8M$89.3M$92.3M$23.7M
Net debt$22.8M-$-18.86M-$-40.3M-$-23.27M-$-113.97M
Cash flow statement
20252024202320222021
Net income-$-114.2M-$-147.79M-$-84.03M-$-129.62M-$-79.56M
Depreciation and amortization$12.7M$12.7M$13.7M$8.6M$7.87M
Stock-based compensation$22.1M$25.2M$27.7M$28.6M$20.8M
Change in working capital$28M$29.6M-$-980K$9.62M$31.3M
Accounts receivable-$-7.27M$9.43M$4.83M$5.17M$16.7M
Inventory$430K-$-390K$0.00$0.00$0.00
Accounts payable-$-12.31M$10.7M$2.33M$3.74M$13.4M
Net cash provided by operating activities-$-46.36M-$-104.5M-$-105.36M-$-73.1M-$-10.53M
Investments in property, plant and equipment-$-3.83M-$-4.96M-$-20.17M-$-44.96M-$-55.22M
Acquisitions, net$0.00$0.00$0.00$0.00-$-6.5M
Net cash used for investing activities-$-4.11M$23.5M$34M-$-44.96M-$-61.72M
Common stock issued$15.3M$59.4M$92M$25M$1.71M
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$12.3M$54.5M$84M$95.2M$1.71M
Net change in cash-$-37.48M-$-24.98M$15.1M-$-22.19M-$-71.82M
Cash at end of period$68.2M$105.7M$130.7M$115.5M$137.7M
Operating cash flow-$-46.36M-$-104.5M-$-105.36M-$-73.1M-$-10.53M
Capital expenditure-$-3.83M-$-4.96M-$-20.17M-$-44.96M-$-55.22M
Free cash flow-$-50.19M-$-109.45M-$-125.54M-$-118.06M-$-65.75M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About MeiraGTx Holdings plc

        MeiraGTx Holdings plc operates as a clinical-stage gene therapy company, dedicated to pioneering therapeutic solutions for individuals afflicted by serious illnesses. Its development efforts span a broad spectrum of conditions, encompassing ocular diseases like inherited forms of blindness, as well as xerostomia (dry mouth) that often follows radiation treatment for head and neck cancers. The company also targets various degenerative and neurodegenerative disorders, notably amyotrophic lateral sclerosis (ALS) and Parkinson's disease. Currently, several of its programs are in active clinical development, including Phase 1/2 trials for Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, radiation-induced Xerostomia, and Parkinson's. MeiraGTx is also preparing to commence a clinical program for xerostomia linked to Sjogren's syndrome and maintains preclinical initiatives for other neurodegenerative conditions. A key collaboration exists with Janssen Pharmaceuticals, Inc. to advance regulatable gene therapy treatments, leveraging MeiraGTx's proprietary riboswitch technology. Established in 2015, MeiraGTx Holdings plc is headquartered in New York, New York.

        CEO
        Alexandria Forbes
        Employees
        409
        Beta
        1.21

        Explore

        Frequently asked questions

        What is the intrinsic value of MeiraGTx Holdings plc (MGTX)?

        MeiraGTx Holdings plc (MGTX) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is MGTX undervalued?

        MGTX trades at a price of $7.98 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.